S1304, A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 06 Oct 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Feb 2018.
- 25 Jul 2016 Status changed from recruiting to active, no longer recruiting.